Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200510023031external-prioritypatent/DE102005023031B4/en
Priority claimed from DE102006016285Aexternal-prioritypatent/DE102006016285A1/en
Application filed by Merck & Cie, Bayer Ip GmbhfiledCriticalMerck & Cie
Publication of NZ737002ApublicationCriticalpatent/NZ737002A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Steroid Compounds
(AREA)
Abstract
A medicament comprising: 5-methyl-(6S)-tetrahydrofolate, one or more estrogens, selected from the group of ethinylestradiol, mestranol, quinestranol, estradiol, estrone, estrane, estriol, estetroland conjugated equine estrogens and/or progestogens, optionally vitamin B6 and/or vitamin B2,and pharmaceutically acceptable excipients/carriers; in the absence of Vitamin B12. The medicament can be used as an oral contraceptive, and prevents diseases of the consumer caused by folate deficiency, especially cardiovascular diseases, as well as congenital defects caused by folate deficiency after conceiving the embryo, such as neural tube defects, defects of the ventricular valve, urogenital defects, and cheilognathopalatoschisis, without masking the symptoms of vitamin B12 deficiency while facilitating unrestricted usability of the folate component 5-methyl-(6S)-tetrahydrofolate by the organism and thus the biological activity thereof in order to prevent said congenital defects caused by folate deficiency in case of a homozygous or heterozygous methylenetetrahydrofolate reductase polymorphism.
NZ737002A2005-05-132006-05-15Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6s)-tetrahydrofolate
NZ737002A
(en)
Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials
USE OF A STROGEN FOR THE TREATMENT OF DISEASES, CONDITIONS OR SYMPTOMS ASSOCIATED WITH DEFICIENT LEVELS OF STROGENS IN A WOMAN; PHARMACEUTICAL COMPOSITION THAT INCLUDES DAILY DOSAGE UNITS OF ESTRADIOL HEMIDRATE> 0.75 AND 1
Pharmaceutical composition containing a) 2.0 mg of dienogest and 0.015 mg of ethinylestradiol and (6s) -5-methyl-tetrahydrofolate and one or more excipient / vehicles; kit; use for femeneine contraception and reduce the risk of congenital malformations due to lack of folate in pregnancy.